0.876 USD
-0.01 (-0.89%)
Taking everything into account, XAIR scores 3 out of 10 in our fundamental rating. XAIR was compared to 185 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of XAIR have multiple concerns. XAIR is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
XAIR had negative earnings in the past year.
XAIR had a negative operating cash flow in the past year.
XAIR had negative earnings in each of the past 5 years.
In the past 5 years XAIR always reported negative operating cash flow.
1.2 Ratios
XAIR's Return On Assets of -118.51% is on the low side compared to the rest of the industry. XAIR is outperformed by 82.70% of its industry peers.
Looking at the Return On Equity, with a value of -288.20%, XAIR is doing worse than 77.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -118.51% | ||
| ROE | -288.2% | ||
| ROIC | N/A |
ROA(3y)-114.02%
ROA(5y)-88.4%
ROE(3y)-243.66%
ROE(5y)-173.09%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
XAIR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
XAIR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XAIR has more shares outstanding
The number of shares outstanding for XAIR has been increased compared to 5 years ago.
The debt/assets ratio for XAIR is higher compared to a year ago.
2.2 Solvency
XAIR has an Altman-Z score of -16.24. This is a bad value and indicates that XAIR is not financially healthy and even has some risk of bankruptcy.
XAIR has a Altman-Z score of -16.24. This is amonst the worse of the industry: XAIR underperforms 85.95% of its industry peers.
A Debt/Equity ratio of 0.79 indicates that XAIR is somewhat dependend on debt financing.
The Debt to Equity ratio of XAIR (0.79) is worse than 71.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.24 |
ROIC/WACCN/A
WACC10.43%
2.3 Liquidity
XAIR has a Current Ratio of 4.24. This indicates that XAIR is financially healthy and has no problem in meeting its short term obligations.
XAIR has a Current ratio of 4.24. This is in the better half of the industry: XAIR outperforms 71.35% of its industry peers.
XAIR has a Quick Ratio of 3.73. This indicates that XAIR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.73, XAIR is in the better half of the industry, outperforming 74.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.24 | ||
| Quick Ratio | 3.73 |
3. Growth
3.1 Past
XAIR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.12%, which is quite impressive.
Looking at the last year, XAIR shows a very strong growth in Revenue. The Revenue has grown by 147.74%.
Measured over the past years, XAIR shows a very strong growth in Revenue. The Revenue has been growing by 21.66% on average per year.
EPS 1Y (TTM)73.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.68%
Revenue 1Y (TTM)147.74%
Revenue growth 3YN/A
Revenue growth 5Y21.66%
Sales Q2Q%127.82%
3.2 Future
XAIR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.44% yearly.
XAIR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 80.94% yearly.
EPS Next Y78.29%
EPS Next 2Y37.99%
EPS Next 3Y25.6%
EPS Next 5Y15.44%
Revenue Next Year111.92%
Revenue Next 2Y131.66%
Revenue Next 3Y134%
Revenue Next 5Y80.94%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
XAIR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XAIR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
XAIR's earnings are expected to grow with 25.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.99%
EPS Next 3Y25.6%
5. Dividend
5.1 Amount
XAIR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:XAIR (1/12/2026, 8:00:02 PM)
0.876
-0.01 (-0.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners20.02%
Inst Owner Change-0.03%
Ins Owners5.77%
Ins Owner Change0.07%
Market Cap7.02M
Revenue(TTM)5.80M
Net Income(TTM)-36.70M
Analysts80
Price Target9.18 (947.95%)
Short Float %3.88%
Short Ratio0.52
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-25.24%
Min EPS beat(2)-43.33%
Max EPS beat(2)-7.14%
EPS beat(4)2
Avg EPS beat(4)-3.68%
Min EPS beat(4)-43.33%
Max EPS beat(4)27.68%
EPS beat(8)6
Avg EPS beat(8)4.83%
EPS beat(12)7
Avg EPS beat(12)-0.4%
EPS beat(16)8
Avg EPS beat(16)-10.42%
Revenue beat(2)0
Avg Revenue beat(2)-14.84%
Min Revenue beat(2)-28.34%
Max Revenue beat(2)-1.35%
Revenue beat(4)1
Avg Revenue beat(4)-8.9%
Min Revenue beat(4)-28.34%
Max Revenue beat(4)12.72%
Revenue beat(8)1
Avg Revenue beat(8)-16.12%
Revenue beat(12)1
Avg Revenue beat(12)-38.6%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-19.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)29.55%
EPS NY rev (1m)0%
EPS NY rev (3m)13.32%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-42.3%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-36.74%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.21 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.55 | ||
| P/tB | 0.6 | ||
| EV/EBITDA | N/A |
EPS(TTM)-7.58
EYN/A
EPS(NY)-1.51
Fwd EYN/A
FCF(TTM)-3.26
FCFYN/A
OCF(TTM)-2.95
OCFYN/A
SpS0.72
BVpS1.59
TBVpS1.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -118.51% | ||
| ROE | -288.2% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-114.02%
ROA(5y)-88.4%
ROE(3y)-243.66%
ROE(5y)-173.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 76.07% | ||
| Cap/Sales | 42.73% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.24 | ||
| Quick Ratio | 3.73 | ||
| Altman-Z | -16.24 |
F-Score3
WACC10.43%
ROIC/WACCN/A
Cap/Depr(3y)311.89%
Cap/Depr(5y)350.75%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.68%
EPS Next Y78.29%
EPS Next 2Y37.99%
EPS Next 3Y25.6%
EPS Next 5Y15.44%
Revenue 1Y (TTM)147.74%
Revenue growth 3YN/A
Revenue growth 5Y21.66%
Sales Q2Q%127.82%
Revenue Next Year111.92%
Revenue Next 2Y131.66%
Revenue Next 3Y134%
Revenue Next 5Y80.94%
EBIT growth 1Y40.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year98.55%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.12%
OCF growth 3YN/A
OCF growth 5YN/A
BEYOND AIR INC / XAIR FAQ
What is the fundamental rating for XAIR stock?
ChartMill assigns a fundamental rating of 3 / 10 to XAIR.
Can you provide the valuation status for BEYOND AIR INC?
ChartMill assigns a valuation rating of 1 / 10 to BEYOND AIR INC (XAIR). This can be considered as Overvalued.
How profitable is BEYOND AIR INC (XAIR) stock?
BEYOND AIR INC (XAIR) has a profitability rating of 0 / 10.
What is the financial health of BEYOND AIR INC (XAIR) stock?
The financial health rating of BEYOND AIR INC (XAIR) is 3 / 10.